Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000566196 | SCV000665948 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-08-23 | criteria provided, single submitter | clinical testing | The p.S2414L variant (also known as c.7241C>T), located in coding exon 13 of the BRCA2 gene, results from a C to T substitution at nucleotide position 7241. The serine at codon 2414 is replaced by leucine, an amino acid with dissimilar properties. A homology-directed repair activity assay showed that this alteration has no effect on BRCA2 function (Guidugli L et al. Cancer Res. 2013 Jan 1;73(1):265-75). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV000566196 | SCV000908257 | likely benign | Hereditary cancer-predisposing syndrome | 2015-08-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002054867 | SCV002366724 | likely benign | Hereditary breast ovarian cancer syndrome | 2021-05-17 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000113737 | SCV004844382 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-06-08 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004566835 | SCV005059206 | uncertain significance | Familial cancer of breast | 2023-11-02 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000113737 | SCV000147057 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2003-12-23 | no assertion criteria provided | clinical testing |